HRMY
Harmony Biosciences Holdings
39.90$
+0.7%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39.4% | 45.5% | 20.1% | 24.7% | 37.9% | 37.5% | 18.4% | 39.6% | 45.4% | 51.7% | 12.9% | 35.4% | 37.0% | |
| 4.6% | 3.6% | 4.1% | 3.6% | 3.3% | 3.0% | 3.3% | 3.0% | 2.6% | 3.0% | 2.8% | 2.3% | 2.7% | |
| 5.0% | 5.3% | 6.7% | 6.3% | 6.2% | 5.0% | 6.7% | 5.7% | 4.5% | 4.2% | 4.9% | 3.6% | 4.3% | |
| 4.2% | 18.8% | -11.5% | -12.0% | 12.8% | 7.9% | -16.0% | 6.7% | 13.4% | 30.4% | -23.0% | 1.8% | 6.4% | |
| 0.0% | 0.1% | 0.0% | 0.4% | 0.0% | 0.3% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| -0.5% | -21.4% | -4.0% | -31.7% | 0.4% | -3.6% | 1.3% | -9.8% | -2.0% | -7.2% | -85.3% | -50.3% | -35.2% | |
| 34.4% | 32.8% | – | – | – | – | – | – | – | – | – | – | – | |
| -31.2% | -29.7% | – | -0.2% | 0.1% | 0.0% | -0.7% | – | – | – | – | -0.4% | – | |
| – | – | – | – | -2.0% | -1.9% | -2.0% | -1.9% | -1.6% | -2.1% | -2.3% | -1.9% | -2.0% | |
| -34.4% | -31.8% | -2.4% | -2.0% | -0.6% | -1.4% | -0.2% | -1.3% | -1.3% | -1.2% | -3.4% | -0.2% | -1.4% | |
| 4.5% | -7.7% | 13.8% | -9.1% | 37.7% | 32.6% | 19.5% | 28.5% | 42.2% | 43.3% | -75.7% | -15.2% | 0.4% | |
| 39.4% | 45.5% | 20.1% | 24.3% | 37.9% | 37.3% | 18.3% | 39.6% | 45.4% | 51.7% | 12.9% | 35.4% | 37.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.